Invasive pneumococcal disease (IPD) burden

What is IPD?

IPD occurs when Streptococcus pneumoniae invades normally sterile sites in the body, such as the blood or cerebrospinal fluid. IPD can lead to serious illness and hospitalization, and can sometimes be fatal.¹

Some adults, including older adults or those with certain chronic medical conditions or immunocompromising conditions, are at increased risk for IPD and its serious, sometimes life-threatening complications.¹

Serotype 3: the leading cause of IPD in the US²

While there are ~100 known pneumococcal serotypes, not all serotypes contribute equally to the burden of IPD.^1,2,3

Over the last decade, serotype 3 has been a significant cause of IPD in adults.³ In fact, serotype 3 is the leading cause of IPD in the United States and it contributes to ~15% of cases in adults.^2,a The thicker polysaccharide capsule of serotype 3 allows bacteria to evade host immune defenses, contributing to its virulence.⁴

That’s about 1 in 6 cases^2,a

^aCDC Active Bacterial Core surveillance data, 2017-2018.

VAXNEUVANCE immunogenicity

<strong>VAXNEUVANCE immunogenicity</strong>

CDC, Centers for Disease Control and Prevention.

References

Centers for Disease Control and Prevention (CDC). Pneumococcal disease. Last reviewed August 18, 2021. Accessed March 3, 2023. www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html
ACIP. Introduction of the pneumococcal work group. Updated October 28, 2020. Accessed March 3, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-10/pneumo-01-Poehling-Kobayashi-508.pdf
Pilishvili T, Gierke R, Farley M, et al. Epidemiology of invasive pneumococcal disease (IPD) following 18 years of pneumococcal conjugate vaccine (PCV) use in the United States. International Symposium on Pneumococci and Pneumococcal Disease, June 21-24, 2020, Toronto Canada. Poster Presentation.
Sugimoto N, Yamagishi Y, Hirai J, et al. Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: A case report and literature review. BMC Res Notes. 2018;10:21. doi:10.1186/s13104-016-2353-3

Indications

Indication for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Indication for PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent)

PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Select Safety Information for VAXNEUVANCE

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

The most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection-site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection-site swelling (21.7%), injection-site erythema (15.1%), and arthralgia (12.7%).

The most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection-site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection-site swelling (15.4%), injection-site erythema (10.9%), and arthralgia (7.7%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Select Safety Information for PNEUMOVAX 23

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.

Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 for the first time in a clinical trial, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

For subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.